利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

8 条记录 (耗时 0.046 秒)

    Novel forms of T cell costimulatory molecules and uses therefor
    5.
    发明申请
    Novel forms of T cell costimulatory molecules and uses therefor 失效
    新型形式的T细胞共刺激分子及其用途

    公开(公告)号：US20070106070A1

    公开(公告)日：2007-05-10

    申请号：US11589275

    申请日：2006-10-26

    申请人： Arlene Sharpe ,  Francescopaolo Borriello ,  Gordon Freeman ,  Lee Nadler

    发明人： Arlene Sharpe ,  Francescopaolo Borriello ,  Gordon Freeman ,  Lee Nadler

    IPC分类号： C07H21/04

    CPC分类号： C07K14/70532 ,  A01K2217/05

    摘要： Novel structural forms of T cell costimulatory molecules are described. These structural forms comprise a novel structural domain or have a structural domain deleted or added. The structural forms correspond to naturally-occurring alternatively spliced forms of T cell costimulatory molecules or variants thereof which can be produced by standard recombinant DNA techniques. In one embodiment, the T cell costimulatory molecule of the invention contains a novel cytoplasmic domain. In another embodiment, the T cell costimulatory molecule of the invention contains a novel signal peptide domain or has an immunoglobulin variable region-like domain deleted. The novel structural forms of T cell costimulatory molecules can be used to identify agents which stimulate the expression of alternative forms of costimulatory molecules and to identify components of the signal transduction pathway which results in costimulation of T cells.

    摘要翻译： 描述了T细胞共刺激分子的新型结构形式。 这些结构形式包括一个新的结构域或者具有缺失或添加的结构域。 结构形式对应于可以通过标准重组DNA技术产生的天然存在的可变剪接形式的T细胞共刺激分子或其变体。 在一个实施方案中，本发明的T细胞共刺激分子含有新的细胞质结构域。 在另一个实施方案中，本发明的T细胞共刺激分子含有新的信号肽结构域或具有免疫球蛋白可变区域结构域缺失。 T细胞共刺激分子的新型结构形式可用于鉴定刺激替代形式的共刺激分子表达的试剂，并鉴定导致T细胞共刺激的信号转导通路的成分。

    Agents that modulate immune cell activation and methods of use thereof
    6.
    发明申请
    Agents that modulate immune cell activation and methods of use thereof 有权
    调节免疫细胞活化的药剂及其使用方法

    公开(公告)号：US20070065427A1

    公开(公告)日：2007-03-22

    申请号：US11501392

    申请日：2006-08-09

    申请人： Gordon Freeman ,  Arlene Sharpe ,  Janet Buhlman ,  Didier Mandelbrot

    发明人： Gordon Freeman ,  Arlene Sharpe ,  Janet Buhlman ,  Didier Mandelbrot

    IPC分类号： A61K39/395

    CPC分类号： G01N33/6854 ,  A61K38/1709 ,  G01N33/505 ,  G01N33/6872 ,  G01N2333/70532 ,  G01N2500/02

    摘要： Disclosed are methods for identifying an agent that modulates an immune response. One such method comprises screening for agents which inhibit the interaction between a PD-1 ligand and a PD-1 polypeptide, and determining whether the agents inhibit the interaction between a PD-1 ligand and a B7 polypeptide, to identify an agent that inhibits PD-1 ligand and PD-1 polypeptide interaction, while not inhibiting the interaction between a PD-1 ligand and a B7 polypeptide, as an agent that modulates an immune response. Another such method comprises screening for agents which inhibit the interaction between a PD-1 ligand and a B7 polypeptide, and determining whether the agents inhibit the interaction between a PD-1 ligand and a PD-1 polypeptide, to identify an agent that inhibits the PD-1 ligand and B7 polypeptide interaction, which does not inhibit the interaction between a PD-1 ligand and a PD-1 polypeptide, as an agent that modulates the immune response. Further disclosed is a method for inhibiting the interaction between a B7 polypeptide and a PD-1 ligand, the method comprising contacting an immune cell bearing a PD-1 ligand, or an immune cell bearing a B7 polypeptide, with an agent that inhibits the interaction between the PD-1 ligand and the B7 polypeptide. Such agents may be an anti-PD-1 ligand antibody or a small molecule. Also disclosed is a method for modulating an immune response. The method comprises contacting an immune cell bearing the PD-1 ligand, or an immune cell bearing the PD-1 polypeptide, with an agent that inhibits interactions between the PD-1 ligand and the PD-1 polypeptide, without inhibiting interactions between the PD-1 ligand and a B7 polypeptide, to thereby modulate an immune response. The agent may be an anti-PD-1 ligand antibody or a small molecule.

    摘要翻译： 公开了用于鉴定调节免疫应答的药剂的方法。 一种这样的方法包括筛选抑制PD-1配体和PD-1多肽之间相互作用的试剂，以及确定试剂是否抑制PD-1配体和B7多肽之间的相互作用，以鉴定抑制PD -1配体和PD-1多肽相互作用，而不抑制PD-1配体和B7多肽之间的相互作用，作为调节免疫应答的试剂。 另一种这样的方法包括筛选抑制PD-1配体和B7多肽之间的相互作用的试剂，以及确定试剂是否抑制PD-1配体和PD-1多肽之间的相互作用，以鉴定抑制 PD-1配体和B7多肽相互作用，其不抑制PD-1配体和PD-1多肽之间的相互作用，作为调节免疫应答的试剂。 进一步公开的是抑制B7多肽和PD-1配体之间的相互作用的方法，该方法包括将带有PD-1配体的免疫细胞或带有B7多肽的免疫细胞与抑制相互作用的药物接触 在PD-1配体和B7多肽之间。 这样的试剂可以是抗PD-1配体抗体或小分子。 还公开了一种调节免疫应答的方法。 该方法包括使携带PD-1配体或携带PD-1多肽的免疫细胞的免疫细胞与抑制PD-1配体和PD-1多肽之间的相互作用的试剂接触，而不抑制PD之间的相互作用 -1配体和B7多肽，从而调节免疫应答。 该试剂可以是抗PD-1配体抗体或小分子。